 Buprenorphine
"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.
| Descriptor ID |
D002047
|
| MeSH Number(s) |
D03.132.577.249.150 D03.549.686.150 D03.605.497.150 D04.615.723.795.150
|
| Concept/Terms |
Subutex- Subutex
- Essex Brand of Buprenorphine Hydrochloride
- Grünenthal Brand of Buprenorphine
- Buprenorphine Grünenthal Brand
- Grünenthal Brand of Buprenorphine Hydrochloride
- Temgésic
- Reckitt Benckiser Brand of Buprenorphine Hydrochloride
- Reckitt Brand of Buprenorphine Hydrochloride
- Schering-Plough Brand of Buprenorphine Hydrochloride
- Schering Plough Brand of Buprenorphine Hydrochloride
- Temgesic
- Buprex
- Reckitt & Colman Brand 2 of Buprenorphine Hydrochloride
Prefin- Prefin
- Key Brand of Buprenorphine Hydrochloride
6029-M- 6029-M
- 6029 M
- 6029M
- RX-6029-M
- RX 6029 M
- RX6029M
Buprenex- Buprenex
- Reckitt & Colman Brand 1 of Buprenorphine Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Buprenorphine".
Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".
This graph shows the total number of publications written about "Buprenorphine" by people in UAMS Profiles by year, and whether "Buprenorphine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 3 | 2 | 5 | | 2023 | 5 | 0 | 5 | | 2022 | 5 | 1 | 6 | | 2021 | 4 | 0 | 4 | | 2020 | 4 | 1 | 5 | | 2019 | 4 | 1 | 5 | | 2018 | 2 | 1 | 3 | | 2017 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2015 | 0 | 1 | 1 | | 2014 | 0 | 2 | 2 | | 2013 | 3 | 1 | 4 | | 2012 | 1 | 0 | 1 | | 2011 | 4 | 0 | 4 | | 2010 | 1 | 0 | 1 | | 2009 | 2 | 0 | 2 | | 2008 | 0 | 1 | 1 | | 2005 | 1 | 1 | 2 | | 2004 | 2 | 0 | 2 | | 2003 | 2 | 1 | 3 | | 2002 | 1 | 1 | 2 | | 2001 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 1996 | 3 | 0 | 3 | | 1995 | 4 | 0 | 4 | | 1994 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Buprenorphine" by people in Profiles over the past ten years.
-
Fortney JC, Ratzliff AD, Blanchard BE, Ferro L, Rouvere J, Chase E, Duncan MH, Merrill JO, Simpson T, Williams EC, Austin EJ, Curran GM, Schoenbaum M, Heagerty PJ, Saxon AJ. Collaborating to heal addiction and mental health in primary care (CHAMP): A protocol for a hybrid type 2a trial. Contemp Clin Trials. 2024 Nov; 146:107700.
-
Jones CM, Shoff C, Blanco C, Losby JL, Ling SM, Compton WM. Overdose, Behavioral Health Services, and Medications for Opioid Use Disorder After a Nonfatal Overdose. JAMA Intern Med. 2024 Aug 01; 184(8):954-962.
-
Hayes CJ, Martin BC, Hoggatt KJ, Cucciare MA, Hudson TJ, Gordon AJ. Average Daily Dose Trajectories for Episodes of Buprenorphine Treatment for Opioid Use Disorder. Subst Use Addctn J. 2024 Oct; 45(4):727-735.
-
Hayes CJ, Raciborski RA, Martin BC, Gordon AJ, Hudson TJ, Brown CC, Pro G, Cucciare MA. Are gaps in rates of retention on buprenorphine for treatment of opioid use disorder closing among veterans across different races and ethnicities? A retrospective cohort study. J Subst Use Addict Treat. 2024 Nov; 166:209461.
-
Marshall SA, Siebenmorgen LE, Youngen K, Borders T, Zaller N. Primary Care Providers' Experiences Treating Opioid Use Disorder Using Telehealth in the Height of the COVID-19 Pandemic. J Prim Care Community Health. 2024 Jan-Dec; 15:21501319241246359.
-
Fortney JC, Ratzliff AD, Blanchard BE, Johnson M, Ferro L, Austin EJ, Williams EC, Duncan MH, Merrill JO, Thomas J, Kitay B, Schoenbaum M, Heagerty PJ, Saxon AJ. Does Screening for Opioid Use Disorder in Primary Care Increase the Percentage of Patients With a New Diagnosis? Ann Intern Med. 2023 10; 176(10):1431-1433.
-
Tsai PF, Oliveto AH, Landes RD, Mancino MJ. Characteristics of patients undergoing medication-assisted -treatment for opioid use disorder and their interest in Tai Chi practice. J Opioid Manag. 2023 Jul-Aug; 19(4):329-341.
-
Tobacyk J, Parks BJ, Salazar P, Coward LU, Berquist MD, Gorman GS, Brents LK. Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome. Drug Alcohol Depend. 2023 08 01; 249:110832.
-
Jones CM, Shoff C, Blanco C, Losby JL, Ling SM, Compton WM. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic. JAMA Psychiatry. 2023 05 01; 80(5):508-514.
-
Shah NK, Chandler MW, Cetto AV, Luciani LL, Painter J, Bailey D. Retrospective Cohort Study of Safety Outcomes Associated with Opioid Rotations to Buprenorphine. J Pain Palliat Care Pharmacother. 2023 Sep; 37(3):234-245.
-
Costa RS, Ciotti-McClallen M, Tilley R, Perry S, Maki L, Starks D, Stein AB. Intramuscular alfaxalone with or without buprenorphine or hydromorphone provides sedation with minimal adverse effects in healthy rabbits (Oryctolagus cuniculus) in a randomized blinded controlled trial. J Am Vet Med Assoc. 2022 12 15; 261(2):223-228.
-
Jones CM, Shoff C, Hodges K, Blanco C, Losby JL, Ling SM, Compton WM. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic. JAMA Psychiatry. 2022 10 01; 79(10):981-992.
-
Griffith PS, Brown LM, Lensing SY, Nahata R, Padala PR, Snow L, Milholland K, Mullins M. Opioid Use Disorder: Treatment Outcomes in U.S. Veterans. J Addict Nurs. 2022 Oct-Dec 01; 33(4):322-325.
-
Gokarakonda SB, Boydstun JM, Yilanli M, Han X, Kumar N, Oliveto AH, Mancino MJ. Impact of state and trait anxiety severity on retention and phase advancement in an outpatient buprenorphine treatment program. Am J Addict. 2022 05; 31(3):219-225.
-
Pro G, Hayes C, Brown CC, Goree J, Zaller N. Individual and Health Policy Factors Associated With Positive Heroin and Opioid Treatment Response: United States, 2018. Am J Public Health. 2022 02; 112(S1):S66-S76.
-
Hayes CJ, Cucciare MA, Martin BC, Hudson TJ, Bush K, Lo-Ciganic W, Yu H, Charron E, Gordon AJ. Using data science to improve outcomes for persons with opioid use disorder. Subst Abus. 2022; 43(1):956-963.
-
Phillips SJ, Oliveto A, Mancino MJ, Hendrickson HP. Development and validation of a rapid liquid chromatography/tandem mass spectrometry method to quantitate gabapentin and buprenorphine in human serum. Rapid Commun Mass Spectrom. 2021 Jul 31; 35(14):e9104.
-
Hawk K, Hoppe J, Ketcham E, LaPietra A, Moulin A, Nelson L, Schwarz E, Shahid S, Stader D, Wilson MP, D'Onofrio G. Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department. Ann Emerg Med. 2021 09; 78(3):434-442.
-
Lin LA, Fortney JC, Bohnert ASB, Coughlin LN, Zhang L, Piette JD. Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder. J Subst Abuse Treat. 2022 02; 133:108492.
-
Coker JL, Ray-Griffith SL, McLeod C, Han X, Mancino M, Kearns GL, Stowe ZN. Clearance of buprenorphine during pregnancy and neonatal outcomes. Arch Womens Ment Health. 2021 12; 24(6):933-939.
-
Ray-Griffith S, Tharp E, Coker JL, Catlin D, Knight B, Stowe ZN. Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention. Am J Addict. 2021 01; 30(1):43-48.
-
Gibbs HM, Price D, Delgado PL, Clothier JL, C?ceda R. Buprenorphine use for pain and suicidal ideation in severely suicidal patients. Int J Psychiatry Med. 2020 11; 55(6):387-396.
-
Pro G, Utter J, Haberstroh S, Baldwin JA. Dual mental health diagnoses predict the receipt of medication-assisted opioid treatment: Associations moderated by state Medicaid expansion status, race/ethnicity and gender, and year. Drug Alcohol Depend. 2020 04 01; 209:107952.
-
Saunders EC, Moore SK, Walsh O, Metcalf SA, Budney AJ, Scherer E, Marsch LA. Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders. J Subst Abuse Treat. 2020 04; 111:54-66.
-
Peterson LE, Morgan ZJ, Borders TF. Practice Predictors of Buprenorphine Prescribing by Family Physicians. J Am Board Fam Med. 2020 Jan-Feb; 33(1):118-123.
-
Hansen E, Nadagoundla C, Wang C, Miller A, Case AA. Buprenorphine for Cancer Pain in Patients With Nonmedical Opioid Use: A Retrospective Study at a Comprehensive Cancer Center. Am J Hosp Palliat Care. 2020 May; 37(5):350-353.
-
Kroska EB, Meller EW, Doyle R, Coker JL, Knight BT, Ray-Griffith SL, Nembhard WN, Stowe ZN. Drug screening during pregnancy: Urine dip cups measure up. Drug Alcohol Depend. 2019 11 01; 204:107461.
-
Bolin EH, Escalona-Vargas D, Daily JA, Siegel ER, Lowery CL, Coker J, Stowe ZN, Eswaran H. Magnetocardiographic identification of prolonged fetal corrected QT interval in women receiving treatment for opioid use disorder. J Obstet Gynaecol Res. 2019 Oct; 45(10):1989-1996.
-
Griffin BA, Caperton CO, Russell LN, Cabanlong CV, Wilson CD, Urquhart KR, Martins BS, Zita MD, Patton AL, Alund AW, Owens SM, Fantegrossi WE, Moran JH, Brents LK. In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome. J Pharmacol Exp Ther. 2019 07; 370(1):9-17.
-
Lake EP, Mitchell BG, Shorter DI, Kosten T, Domingo CB, Walder AM. Buprenorphine for the treatment of posttraumatic stress disorder. Am J Addict. 2019 02; 28(2):86-91.
-
Wen H, Borders TF, Cummings JR. Trends In Buprenorphine Prescribing By Physician Specialty. Health Aff (Millwood). 2019 01; 38(1):24-28.
-
Coker JL, Catlin D, Ray-Griffith S, Knight B, Stowe ZN. Buprenorphine medication-assisted treatment during pregnancy: An exploratory factor analysis associated with adherence. Drug Alcohol Depend. 2018 11 01; 192:146-149.
-
Gressler LE, Titus-Glover D, Shaya FT. Treatment modalities for pregnant women with opioid use disorder. Lancet. 2018 08 18; 392(10147):551.
-
Escalona-Vargas D, Coker JL, Ray-Griffith S, Siegel ER, Lowery CL, Stowe ZN, Eswaran H. Fetal assessment in buprenorphine-maintained women using fetal magnetoencephalography: a pilot study. Addiction. 2018 10; 113(10):1895-1904.
-
Wen H, Hockenberry JM, Borders TF, Druss BG. Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment. Med Care. 2017 04; 55(4):336-341.
-
Kumar N, Stowe ZN, Han X, Mancino MJ. Impact of early childhood trauma on retention and phase advancement in an outpatient buprenorphine treatment program. Am J Addict. 2016 10; 25(7):542-8.
-
Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis. 2016; 35(1):22-35.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|